A detailed history of Hc Financial Advisors Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hc Financial Advisors Inc holds 27,448 shares of BMY stock, worth $1.57 Million. This represents 1.41% of its overall portfolio holdings.

Number of Shares
27,448
Previous 29,098 5.67%
Holding current value
$1.57 Million
Previous $2.13 Million 0.56%
% of portfolio
1.41%
Previous 1.26%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 25, 2022

SELL
$72.62 - $79.98 $119,823 - $131,967
-1,650 Reduced 5.67%
27,448 $2.11 Million
Q1 2022

May 04, 2022

SELL
$61.48 - $73.72 $6,762 - $8,109
-110 Reduced 0.38%
29,098 $2.13 Million
Q4 2021

Jan 19, 2022

BUY
$53.63 - $62.52 $150,432 - $175,368
2,805 Added 10.62%
29,208 $1.82 Million
Q3 2021

Oct 19, 2021

BUY
$59.17 - $69.31 $142,363 - $166,759
2,406 Added 10.03%
26,403 $1.56 Million
Q2 2021

Jul 28, 2021

BUY
$61.91 - $67.42 $40,241 - $43,823
650 Added 2.78%
23,997 $1.6 Million
Q1 2021

Apr 21, 2021

BUY
$59.34 - $66.74 $161,820 - $181,999
2,727 Added 13.23%
23,347 $1.47 Million
Q4 2020

Jan 26, 2021

BUY
$57.74 - $65.43 $87,764 - $99,453
1,520 Added 7.96%
20,620 $1.28 Million
Q3 2020

Oct 30, 2020

BUY
$57.43 - $63.64 $74,084 - $82,095
1,290 Added 7.24%
19,100 $1.15 Million
Q2 2020

Jul 28, 2020

BUY
$54.82 - $64.09 $259,956 - $303,914
4,742 Added 36.29%
17,810 $1.05 Million
Q1 2020

Apr 08, 2020

BUY
$46.4 - $67.43 $75,864 - $110,248
1,635 Added 14.3%
13,068 $728,000
Q4 2019

Jan 17, 2020

BUY
$49.21 - $64.19 $562,617 - $733,884
11,433 New
11,433 $734,000
Q4 2018

Jan 25, 2019

SELL
$48.76 - $63.23 $154,959 - $200,944
-3,178 Closed
0 $0
Q1 2018

May 07, 2018

BUY
$59.92 - $68.98 $190,425 - $219,218
3,178 New
3,178 $201,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hc Financial Advisors Inc Portfolio

Follow Hc Financial Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hc Financial Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hc Financial Advisors Inc with notifications on news.